

## Utilizing Molecular Diagnostics to Direct Systemic First-Line Therapy for Metastatic Gastric Carcinoma

Resource	Address
Yamada Y, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): An open-label, phase 3, randomised controlled trial. <i>Lancet Gastroenterol Hepatol.</i> 2019;4:501-510.	<a href="https://pubmed.ncbi.nlm.nih.gov/31101534/">https://pubmed.ncbi.nlm.nih.gov/31101534/</a>
Al-Batran SE, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). <i>Eur J Cancer.</i> 2013;49:835-842.	<a href="https://pubmed.ncbi.nlm.nih.gov/23063354/">https://pubmed.ncbi.nlm.nih.gov/23063354/</a>
Guimbaud R, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. <i>J Clin Oncol.</i> 2014;32:3520-3526.	<a href="https://pubmed.ncbi.nlm.nih.gov/25287828/">https://pubmed.ncbi.nlm.nih.gov/25287828/</a>
Kang JH, et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. <i>J Clin Oncol.</i> 2012;30:1513-1518.	<a href="https://pubmed.ncbi.nlm.nih.gov/22412140/">https://pubmed.ncbi.nlm.nih.gov/22412140/</a>
Ford, HER, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. <i>Lancet Oncol.</i> 2014;15:78-86.	<a href="https://pubmed.ncbi.nlm.nih.gov/24332238/">https://pubmed.ncbi.nlm.nih.gov/24332238/</a>
Shitara K, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2018;19:1437-1448.	<a href="https://pubmed.ncbi.nlm.nih.gov/30355453/">https://pubmed.ncbi.nlm.nih.gov/30355453/</a>
Dulak AM, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. <i>Cancer Res.</i> 2012;72:4383-4393.	<a href="https://pubmed.ncbi.nlm.nih.gov/22751462/">https://pubmed.ncbi.nlm.nih.gov/22751462/</a>
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of	<a href="https://pubmed.ncbi.nlm.nih.gov/25079317/">https://pubmed.ncbi.nlm.nih.gov/25079317/</a>

gastric adenocarcinoma. <i>Nature</i> . 2014;513:202-209.	
Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. <i>Lancet</i> . 2010;376:687-697.	<a href="https://pubmed.ncbi.nlm.nih.gov/20728210/">https://pubmed.ncbi.nlm.nih.gov/20728210/</a>
Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> . 2014;383:31-39.	<a href="https://pubmed.ncbi.nlm.nih.gov/24094768/">https://pubmed.ncbi.nlm.nih.gov/24094768/</a>
Wilke H, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. <i>Lancet Oncol</i> . 2014;15:1224-1235.	<a href="https://pubmed.ncbi.nlm.nih.gov/25240821/">https://pubmed.ncbi.nlm.nih.gov/25240821/</a>
Alexandrov LB, et al. Signatures of mutational processes in human cancer. <i>Nature</i> . 2013;500:415-421.	<a href="https://pubmed.ncbi.nlm.nih.gov/23945592/">https://pubmed.ncbi.nlm.nih.gov/23945592/</a>
Fuchs CS, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Ccinical KEYNOTE-059 trial. <i>JAMA Oncol</i> . 2018;4:e180013.	<a href="https://pubmed.ncbi.nlm.nih.gov/29543932/">https://pubmed.ncbi.nlm.nih.gov/29543932/</a>
Kang YK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> . 2017;390:2461-2471.	<a href="https://pubmed.ncbi.nlm.nih.gov/28993052/">https://pubmed.ncbi.nlm.nih.gov/28993052/</a>
Shitara, K, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastroesophageal junction cancer (KEY NOTE-061): A radomised, open-label, controlled, phase 3 trial. <i>Lancet</i> . 2018;392:123-133.	<a href="https://pubmed.ncbi.nlm.nih.gov/29880231/">https://pubmed.ncbi.nlm.nih.gov/29880231/</a>
Shitara K, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer:	<a href="https://pubmed.ncbi.nlm.nih.gov/32880601/">https://pubmed.ncbi.nlm.nih.gov/32880601/</a>

<p>The KEYNOTE-062 phase 3 randomized clinical trial. <i>JAMA Oncol.</i> 2020;6:1571-1580.</p>	
<p>Moehler M, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. <i>Ann Oncol.</i> 2020;31(suppl 4):S1191.</p>	<p><a href="https://www.annalsofoncology.org/article/S0923-7534(20)42378-6/abstract">https://www.annalsofoncology.org/article/S0923-7534(20)42378-6/abstract</a></p>
<p>Boku N, et al. LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. <i>Ann Oncol.</i> 2020;31(suppl 4):S1192.</p>	<p><a href="https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-previously-untreated-advanced-or-recurrent-gastric-gastroesophageal-junction">https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-previously-untreated-advanced-or-recurrent-gastric-gastroesophageal-junction</a></p>
<p>Janjigian YY, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2020;21:821-831.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32437664/">https://pubmed.ncbi.nlm.nih.gov/32437664/</a></p>
<p>Fukuoka S, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). <i>J Clin Oncol.</i> 2020;38:2053-2061.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32343640/">https://pubmed.ncbi.nlm.nih.gov/32343640/</a></p>
<p>Kawazoe A, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): An open-label, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2020;21:1057-1065.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32589866/">https://pubmed.ncbi.nlm.nih.gov/32589866/</a></p>